Scribd
Upload
75 views7 pages

Lim Drug Study

This document summarizes information about the migraine drug Imigran (generic name: sumatriptan). It discusses the drug's classification, mechanism of action, pharmacokinetics, dosing, indications, contraindications, side effects, drug interactions, and the nurse's role in educating patients and monitoring therapy. Sumatriptan is a selective serotonin receptor agonist used to treat acute migraine headaches. Nurses should teach patients about proper use and monitor for side effects like numbness, flushing and drug interactions. The goal is safe and effective treatment of migraine attacks.

Uploaded by

Khovianna Lim
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
75 views7 pages

Lim Drug Study

This document summarizes information about the migraine drug Imigran (generic name: sumatriptan). It discusses the drug's classification, mechanism of action, pharmacokinetics, dosing, indications, contraindications, side effects, drug interactions, and the nurse's role in educating patients and monitoring therapy. Sumatriptan is a selective serotonin receptor agonist used to treat acute migraine headaches. Nurses should teach patients about proper use and monitor for side effects like numbness, flushing and drug interactions. The goal is safe and effective treatment of migraine attacks.

Uploaded by

Khovianna Lim
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 7

IMIGRAN

A Drug Study presented to the


Faculty of the Nursing Department
SAN PEDRO COLLEGE
DAVAO CITY

In Partial Fulfillment of the Requirements in


NCM 206 – PHARMACOLOGY

Submitted to:
MARI KRIS DOCTORA, RN
Clinical Instructor

Submitted by:
KHOVIANNA GERLYN G. LIM, ST.N
BSN 2A

November 19, 2022


Generic: sumatriptan

Brand Name: Imigran

Classification: Selective serotonin receptor agonists

Pregnancy Category: category C

Mode of Action: Sumatriptan is in a class of medications called selective serotonin receptor agonists. It works by
narrowing blood vessels in the head, stopping pain signals from being sent to the brain, and blocking the release of
certain natural substances that cause pain, nausea, and other symptoms of migraine.

Pharmacokinetics:
Absorption
Bioavailability: P.O, 14% (drug is well absorbed but undergoes first-pass metabolism)
Onset: 30-60 min
Duration: ≤24 hr
Peak serum time: 2 hr (PO)

Distribution: Protein binding is low, 14-21%

Metabolism: Metabolized by liver (first-pass)


Elimination: Half-life 2 hours

Excretion: Urine approximately 80% , mainly as metabolites

Suggested Dose:
Adult
 Single 50 or 100 mg dose. If no response to 1st dose, 2nd dose should not be taken for the same attack. If
patient responded to the 1st dose, but symptoms recur, 2nd dose may be given in the next 24 hr provided
not >300 mg is taken in any 24-hr period.

Indication: Acute relief of migraine with or without aura including migraine attacks associated with menstrual period.

Contraindication:
 Pediatrics, elderly, lactating and pregnant mothers
 Hypersensitivity to sumatriptan
 Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic heart disease,
coronary vasospasm (Prinzmetal's angina), peripheral vascular disease or symptoms or signs consistent with
ischaemic heart disease.
 Sumatriptan should not be administered to patients with a history of cerebrovascular accident (CVA) or transient
ischaemic attack (TIA).
 Sumatriptan should not be administered to patients with severe hepatic impairment.
 The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled hypertension is
contraindicated.
 The concomitant administration of ergotamine, or derivatives of ergotamine (including methysergide) or any
triptan/5-hydroxytryptamine1 (5-HT1) receptor agonist is contraindicated (see section 4.5).
 Concurrent administration of monoamine oxidase inhibitors (MAOIs) and sumatriptan is contraindicated.
 Sumatriptan must not be used within 2 weeks of discontinuation of therapy with monoamine oxidase inhibitors.

Side Effects:
Flushing, feelings of tingling/numbness/prickling/heat, tiredness, weakness, drowsiness, or dizziness

Adverse Effects:
 CNS: dizziness, vertigo, anxiety, drowsiness, fatigue, feeling of heaviness, feeling of tightness, headache,
malaise, strange feeling, tight feeling in head, weakness.
 EENT: alterations in vision, nasal sinus discomfort, throat discomfort.
 CV: MI, angina, chest pressure, chest tightness, coronary vasospasm, ECG changes, transient hypertension.
 GI: abdominal discomfort, dysphagia.
 Derm: tingling, warm sensation, burning sensation, cool sensation, flushing. Local: injection-site reaction.
 MS: jaw discomfort, muscle cramps, myalgia, neck pain, neck stiffness. Neuro: numbness.

Drug Interaction:
Not to be given with ergotamine, monoamine oxidase inhibitors, serotonin syndrome with SSRI/selective
nonadrenaline reuptake inhibitors. Not recommended with 5HT1 agonist.
Nursing Responsibilities:
 Patient teaching. Inform patients of the importance of only using their medication for a headache that they
recognise as a migraine.
 R: Medication should be taken as soon as the headache pain begins. Patients who have an aura stage should
wait until the headache pain starts before taking the medication.

 Educate client on drug therapy (indications, pharmacokinetics, side and adverse effects, therapeutic effects)
 R: to promote understanding and compliance of the patient

 Assess for side-effects of tingling, burning, numbness, flushing or feeling of pressure.


 R: To watch out for adverse effects and to ensure client safety

 Assess stress level and mechanisms for coping with migraine.


 R: Mental capacity is important since the level of pain is objective. Migraine may interfere with ADL that can
cause stress and therefore increase headache.

 Provide a calm environment during migraine attack.


 R: Make sure client is comfortable and avoid any stressors.

 Inform client to avoid excessive or chronic alcohol consumption.


 R: Alcohol increased the risk of GI bleeding, ulcer, and perforation when taken with sumatriptan.
 Obtain a list of prescription and nonprescription medications, vitamins, nutritional supplements, and herbal
products that the client is taking or plan to take.
 R: This is to avoid drug to drug interactions that would otherwise reduce the efficacy of the medication or may
cause side effects.

 Inform client to avoid operating heavy machinery or drive.


 R:Imigran causes drowsiness which may affect the ability to perform certain tasks.

 Evaluate. Assess the frequency and severity of headaches, and document


 R: To determine whether drug therapy is successful in decreasing migraine or cluster headache attacks.

 Implement appropriate interventions. Changes in eating habits such as limiting sodium, tyramine, aspartame,
and nitrite-rich foods. Encourage intake of more fluids, leafy greens, and try therapeutic diets like low glycemic
and low tyramine diet.
 R: Reduce the need for drug therapy

References:
Sumatriptan. Sumatriptan | Davis's Drug Guide for Rehabilitation Professionals | F.A. Davis PT Collection | McGraw Hill
Medical. (n.d.). Retrieved November 19, 2022,
from https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139026830

U.S. National Library of Medicine. (n.d.). Sumatriptan: Medlineplus Drug Information. MedlinePlus. Retrieved November
19, 2022, from https://medlineplus.gov/druginfo/meds/a601116.html

You might also like